ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19

@article{Rajter2020ICONI,
  title={ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19},
  author={Juliana Cepelowicz Rajter and Michael S. Sherman and Naaz Fatteh and Fabio Vogel and Jaime Sacks and J J Rajter},
  journal={medRxiv},
  year={2020}
}
Abstract Importance: No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective: To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19. Design and Setting: Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South… 
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
TLDR
Assessment of the efficacy of Ivermectin in mild cases of COVID-19 patients on the basis of predefined assessment criteria found no significant difference between case group who were given ivermECTin along with symptomatic treatment and control group, being asymptomatic on day 7 at follow up.
Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
TLDR
Ivermectin as an adjunct reduced the rate of mortality, low O2 duration, and duration of hospitalization in adult COVID 19 patients and the improvement of other clinical parameters showed that the ivermECTin had a high therapeutic effect on COVID-19.
Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
TLDR
In the intervention arm, early viral clearance was observed and no side effects were documented, therefore ivermectin is a potential addition to the standard care of treatment in COVID-19 patients.
Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion
  • D. Scheim
  • Medicine
    SSRN Electronic Journal
  • 2020
TLDR
The proposed catch and clump scenario for COVID-19 has a parallel in malaria, for which CD147 is central to the infectious process, and a significantly higher rate of capillary flow in younger people could explain a corresponding decreased severity of COIVD-19.
COVID-19: The Ivermectin African Enigma
TLDR
The incidence in mortality rates and number of cases is significantly lower among the APOC countries compared to non-APOC countries, suggesting that a mass public health preventive campaign against COVID-19 may have taken place, inadvertently, in some African countries with massive community ivermectin use.
COVID-19: The Ivermectin African Enigma COVID-19: El enigma africano de la ivermectina
TLDR
The incidence in mortality rates and number of cases is significantly lower among the APOC countries compared to non-APOC countries, suggesting that a mass public health preventive campaign against COVID-19 may have taken place, inadvertently, in some African countries with massive community ivermectin use.
Real-World Effectiveness of Hydroxychloroquine, Azithromycin, and Ivermectin Among Hospitalized COVID-19 Patients: Results of a Target Trial Emulation Using Observational Data from a Nationwide Healthcare System in Peru
TLDR
The results of the target trial emulation match with previous findings of randomized clinical trials and observational studies, which showed no beneficial effects of hydroxychloroquine, ivermectin, azithromycin, or their combinations.
Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study
TLDR
Ivermectin had no beneficial effect on the disease course over usual care in mild to moderate COVID-19 cases in this open-label randomised controlled study.
...
1
2
3
4
5
...

References

SHOWING 1-8 OF 8 REFERENCES
Safety of high-dose ivermectin: a systematic review and meta-analysis.
TLDR
Although within this review the safety of high-dose ivermectin appears to be comparable to standard doses, there are not enough data to support a recommendation for its use in higher-than-approved doses.
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
TLDR
This case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area and assesses outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement therapy, and death.
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
TLDR
Infections with flaviviruses, such as dengue, West Nile virus and the recently re-emerging Zika virus, are an increasing and probably lasting global risk, and broad-spectrum activity is particularly desirable to prepare for the next flaviviral epidemic.
Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus
TLDR
It is established for the first time that ivermectin has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV- 1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively.